<DOC>
	<DOCNO>NCT00866671</DOCNO>
	<brief_summary>This international , multicentre , single arm , phase IV study ass safety efficacy nelarabine child young adult relapse refractory T-lineage acute lymphoblastic leukaemia ( T-ALL ) lymphoblastic lymphoma ( T-LBL ) whose disease respond relapsed follow treatment least two chemotherapy regimen . It post-authorisation safety study ( PASS ) conduct purpose confirm safety profile clinical benefit nelarabine license condition use . The study observational , non-interventional , include approximately 40 child young adult ( 21 year age ) .</brief_summary>
	<brief_title>Observational Study Nelarabine Children Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>â‰¤ 21 year age Relapsed refractory Tlineage acute lymphoblastic leukaemia ( TALL ) lymphoblastic lymphoma ( TLBL ) Prior treatment least two chemotherapy regimen Selected treatment nelarabine Known hypersensitivity active substance . Women childbearing potential unable unwilling use adequate contraceptive measure Males partner child bear potential willing use condom abstinence Patients persistent neurological toxicity ( CTC grade &gt; = grade 2 ) Adolescents ( age 16 year ) adults physician prescribes 1500mg/m2 dose nelarabine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>T-ALL</keyword>
	<keyword>Safety</keyword>
	<keyword>Post Authorisation Safety Study</keyword>
	<keyword>T-LBL</keyword>
	<keyword>Lymphoblastic Lymphoma</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
</DOC>